Answers are grounded in this paper and cite their sources.
Preclinical data show increased antitumor effects with HER1 and HER2 in models using HER3-based vaccines, indicating potential for improved cancer therapies.
Recognition of HER1-ECD, HER2-ECD and HER3-ECD by PAbs generated in rabbits by immunization with the three HER3-based vaccine candidates.
No takes yet. Share an insight, caveat, or question.
Bermúdez-Abreut et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: